CBFβ抑制剂 | 493028-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: CBFβ抑制剂
• 英文名称: 5-Ethyl-4-(4-methoxy-phenyl)-thiazol-2-ylamine
• 英文别名: 5-ethyl-4-(4-methoxyphenyl)-1,3-thiazol-2-amine
• CAS: 493028-20-9
• 化学式: C₁₂H₁₄N₂OS
• mdl: MFCD02232182
• 分子量: 234.32
• InChiKey: QHRCVGXBBIRPTE-UHFFFAOYSA-N

物化性质

• 沸点：
  421.6±40.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：50 mg/ml； DMF:PBS(pH 7.2)(1:1)：0.5 mg/ml； DMSO：30 mg/ml；乙醇：25 mg/ml

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  76.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

文献信息

• Compositions and methods to treat cancer
  申请人：NOVARTIS AG

  公开号：US11530413B2

  公开（公告）日：2022-12-20

  The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

  本公开提供了用于治疗癌症患者的新型个体化疗法、试剂盒、可传输形式的信息和方法，其中癌症可接受抑制剂的治疗，如本文公开的任何靶点的抑制剂。还提供了试剂盒、筛选候选抑制剂的方法以及相关的治疗方法。
• METHODS FOR INDUCING HEMATOPOIETIC STEM CELL SPECIFICITY
  申请人：The Children's Medical Center Corporation

  公开号：EP3672590A1

  公开（公告）日：2020-07-01
• IMPROVING THE EFFICACY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES
  申请人：University of Southern California

  公开号：US20210290676A1

  公开（公告）日：2021-09-23

  The disclosure relates generally to the generation and use of immune effector cells (e.g., T cells, NK cells) engineered to express an immune receptor (e.g., Chimeric Antigen Receptor, Synthetic Immune Receptor, T Cell Receptor etc.) to treat a disease associated with expression of a target antigen.
• [EN] METHODS FOR INDUCING HEMATOPOIETIC STEM CELL SPECIFICITY<br/>[FR] PROCÉDÉS POUR INDUIRE UNE SPÉCIFICITÉ DE CELLULE SOUCHE HÉMATOPOÏÉTIQUE
  申请人：CHILDRENS MEDICAL CT CORP

  公开号：WO2019040448A1

  公开（公告）日：2019-02-28

  Described herein are methods for inducing HSC specification in a cell. Aspects of the invention relate to contacting a cell with a Runx1-CBFβ inhibitor for a specified period of time, and then removing the inhibitor from the cell. In some embodiments of any of the aspects, HSC specificity is maintained long-term.